FDA approves Spravato, first monotherapy nasal spray to treat depression UPI News
FDA Approves Johnson & Johnson’s Nasal Spray for Adults with Treatment-Resistant Depression NTD
FDA Approves Johnson & Johnson Nasal Spray for Depression RetailWire
FDA allows standalone use of nasal spray antidepressant Spravato (esketamine) : Shots - Health News NPR
FDA allows standalone use of nasal spray antidepressant Spravato (esketamine) Voice Of Alexandria
FDA Expands Approval of Esketamine for Depression Medpage Today
Johnson & Johnson's Spravato gains FDA nod to be used as a monotherapy FiercePharma
Can This Nasal Spray Help With Your Depression? Betches
NHS warns Brits on antidepressants to avoid this one fruit Express
FDA Approves Johnson & Johnson's Treatment As First Monotherapy For Treatment-Resistant Depression Benzinga
